ERAS (Erasca Inc) Return on Gross Profit

Official company branding of Erasca Corp (ERAS)

Erasca, Inc. (ERAS) shows a consolidated gross margin reflecting the success of its melanoma therapies and the availability of liquid reserves, with the current metric standing at 0.00. Business stability is supported by oncology's independence from macroeconomic fluctuations. Growth potential is driven by the recruitment of leading biochemists through a long-term incentive system, which strengthens the company's R&D foundation.

erasca.com (ERAS) Return on Gross Profit: for the period 07/04/2022 - 11/19/2026

Analytical breakdowns and data insights for company Erasca (ERAS)

- current quotes and average value forecast:
- business market valuation indicators:
Fundamental valuation:ERAS, Erasca Corp
Mass-produced product of erasca.com

Gross margin determines the efficiency of the operating cycle by measuring the portion of revenue remaining after deducting direct production costs. By analyzing the gross profit percentage, an investor assesses the ability of Erasca, Inc. (ERAS) to control costs during the development of therapies for RAS-dependent tumors, where high R&D expenses and the binary risks of clinical stages directly impact the company's financial stability and capital runway.

Key competitors

Gross Profit Margin BeiGene Ltd. (ONC)|Return on Gross Profit HALO|Gross Profitability RVMD|Return on Gross Profit AAPG (Ascentage)|Return on Gross Profit cgoncology.com CGON|UroGen Pharma - Return on Gross Profit|Gross Profit Rate BCAX|PSNL - Gross Profitability|Gross Profit Rate DCTH (Delcath Corp)|YMAB: Gross Margin|AURA - Return on Sales by Gross Profit|CADL (Candel Therapeutics Inc.) - Gross Margin|Gross Return on Sales ARAY (Accuray)|Return on Gross Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Gross Profit Margin|Gross Profitability Citius Oncology, Inc. CTOR|HURA - Return on Gross Profit|protaratx.com - Gross Margin|FATE - Gross Margin|WHWK: Gross Margin|TScan Therapeutics (TCRX) - Gross Margin|Gross Profitability Champions Oncology|Gross Profitability XBIT|Gross Margin CVM|Return on Gross Profit OS Therapies Inc. OSTX|Gross Profitability Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Gross Profit Margin|ANL - Gross Profitability|Gross Profit Margin verupharma.com|TPST: Gross Margin|XLO - Return on Sales by Gross Profit|Gross Profitability Renovaro|Gross Margin muraloncology.com|Gross Margin KAPA|Return on Sales by Gross Profit OnKure Therapeutics, Inc.|Gross Margin GDTC (w2.cytomed.sg)|CRIS - Return on Gross Profit|Apollomics - Gross Margin|Tharimmune Corp (THAR) - Return on Gross Profit|ADVB: Gross Margin|Return on Gross Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Gross Margin|Gross Return on Sales SBFM (Sunshine Biopharma)|Gross Profitability Xenetic Bio (XBIO)|Gross Profitability SLRX (Salarius Pharma)|Kitov Pharma - Return on Gross Profit|American Oncology Network (AONC) - Gross Profit Margin|BeiGene - Gross Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Gross Profit|ELEV (Elevation Oncology, Inc.) - Return on Gross Profit|iCAD Inc. - Gross Profit Rate|Return on Gross Profit IKNA|Gross Margin notablelabs.com|Return on Gross Profit VIRX (Viracta Therapeutics Inc.)|MOR - Gross Profit Margin|Gross Profitability NAYA Biosciences NAYA|AAPGV - Return on Gross Profit